Q3 2024 EPS Estimates for argenx SE Increased by Analyst (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – William Blair boosted their Q3 2024 EPS estimates for shares of argenx in a report issued on Monday, June 24th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($0.47) for the quarter, up from their previous forecast of ($0.49). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is ($2.89) per share. William Blair also issued estimates for argenx’s Q4 2024 earnings at ($0.46) EPS and FY2024 earnings at ($2.09) EPS.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company raised their price target on shares of argenx from $478.00 to $542.00 and gave the company an “overweight” rating in a report on Monday. Morgan Stanley cut their price target on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a report on Tuesday, May 28th. JPMorgan Chase & Co. cut their price target on shares of argenx from $560.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, May 13th. Robert W. Baird cut their price target on shares of argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Finally, JMP Securities cut their price target on shares of argenx from $471.00 to $468.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $525.42.

argenx Price Performance

Shares of ARGX stock opened at $444.94 on Thursday. The firm has a market cap of $26.44 billion, a P/E ratio of -78.61 and a beta of 0.65. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The firm’s 50-day simple moving average is $381.58 and its 200-day simple moving average is $387.30.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Monday, May 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The firm had revenue of $412.51 million for the quarter, compared to analyst estimates of $404.03 million. During the same period in the prior year, the business earned ($0.52) earnings per share.

Hedge Funds Weigh In On argenx

Hedge funds have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust acquired a new position in argenx in the third quarter worth $28,000. GAMMA Investing LLC boosted its holdings in argenx by 420.0% in the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after purchasing an additional 63 shares during the period. Mather Group LLC. acquired a new position in argenx in the first quarter worth $38,000. FNY Investment Advisers LLC acquired a new position in argenx in the fourth quarter worth $38,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in argenx in the fourth quarter worth $60,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.